Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review

Table 1

Characteristics of the included studies.

Author	Year	Journal	Place/country	Study population	Age group	Study design
Hassan et al. [18]	1995	J Pak Med Assoc	Islamabad Pakistan	PM = 14, SSG = 36	1–5 yrs = 40, <1 yrs = 5, >5 yrs = 5 (mean age = 2.6 yrs)	Cross sectional
Hailu et al. [16]	2010	PLoS Negl Trop Dis	East Africa (Sudan, Ethiopia, and Kenya)	PM = 135, SSG = 135, SSG + PM = 135	4–60 yrs (mean age = 17.8)	Prospective, randomized, open label, 3-arm trial carried out in five centres of East Africa
Jamil et al. [19]	2015	PLoS Negl Trop Dis	Bangladesh	120	5–55 yrs	Phase IIIb open label, multicenter, single-arm trial
Jha et al. [20]	1998	BMJ	Bihar, India	PM 12 mg group = 30, PM 16 mg group = 30, PM 20 mg group = 30, SSG 20 mg group = 30	6–55 yrs	Randomized unblinded controlled trial 4-armed study with 30 patient each for aminosidine dosed 12, 16, or 20 mg/kg/day for 21 days and rest 30 patient for sodium stibogluconate 20 mg/kg/day for 30 days
Musa et al. [21]	2010	PLoS Negl Trop Dis	Sudan	PM 20 mg group = 21, PM 15 mg group = 21	4–60 yrs	Two-armed, randomized open label dose finding phase II study at a single site in Sudan, randomly assigned to 2 groups
Sinha et al. [22]	2011	Journal of Tropical Medicine	Bihar, India	494	2–55 yrs	Phase IV open label trial
Sundar et al. [1]	2007	N. Engl J. Med.	Bihar, India	PM = 501, AmB = 165	5–55 yrs	Open label, prospective, randomized trial comparing paromomycin with amphotericin B (3 : 1 block)
Sundar et al. [23]	2009	Clin Infect Dis	Bihar, India	PM 11 mg for 14 days = 217, PM 11 mg for 21 days = 112	5–55 yrs	Randomized, open label study intended to assess the efficacy and safety of 2 regimens of paromomycin administered intramuscularly